ES2240537T3 - Uso de inhibidores de pde5 para el tratamiento de la eyaculacion precoz. - Google Patents

Uso de inhibidores de pde5 para el tratamiento de la eyaculacion precoz.

Info

Publication number
ES2240537T3
ES2240537T3 ES01983728T ES01983728T ES2240537T3 ES 2240537 T3 ES2240537 T3 ES 2240537T3 ES 01983728 T ES01983728 T ES 01983728T ES 01983728 T ES01983728 T ES 01983728T ES 2240537 T3 ES2240537 T3 ES 2240537T3
Authority
ES
Spain
Prior art keywords
pde5
ethyl
pyrimidin
pyrazolo
patients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES01983728T
Other languages
English (en)
Spanish (es)
Inventor
Mitradev Boolell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PFIZER
Pfizer Inc
Original Assignee
PFIZER
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PFIZER, Pfizer Inc filed Critical PFIZER
Application granted granted Critical
Publication of ES2240537T3 publication Critical patent/ES2240537T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Soy Sauces And Products Related Thereto (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES01983728T 2000-11-20 2001-11-19 Uso de inhibidores de pde5 para el tratamiento de la eyaculacion precoz. Expired - Lifetime ES2240537T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0028245 2000-11-20
GBGB0028245.9A GB0028245D0 (en) 2000-11-20 2000-11-20 New therapeutic use

Publications (1)

Publication Number Publication Date
ES2240537T3 true ES2240537T3 (es) 2005-10-16

Family

ID=9903491

Family Applications (1)

Application Number Title Priority Date Filing Date
ES01983728T Expired - Lifetime ES2240537T3 (es) 2000-11-20 2001-11-19 Uso de inhibidores de pde5 para el tratamiento de la eyaculacion precoz.

Country Status (21)

Country Link
EP (1) EP1335730B1 (https=)
JP (1) JP2004520279A (https=)
KR (1) KR100595807B1 (https=)
CN (1) CN1474692A (https=)
AT (1) ATE296631T1 (https=)
AU (2) AU2002215149B2 (https=)
BR (1) BR0115413A (https=)
CA (1) CA2429114C (https=)
DE (1) DE60111254T2 (https=)
ES (1) ES2240537T3 (https=)
GB (1) GB0028245D0 (https=)
HU (1) HUP0301915A3 (https=)
IL (1) IL155521A0 (https=)
MX (1) MXPA03003586A (https=)
MY (1) MY131573A (https=)
NZ (1) NZ525167A (https=)
PL (1) PL362058A1 (https=)
PT (1) PT1335730E (https=)
TW (1) TWI280132B (https=)
WO (1) WO2002040027A1 (https=)
ZA (1) ZA200302947B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6403597B1 (en) * 1997-10-28 2002-06-11 Vivus, Inc. Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
AU2003903597A0 (en) * 2003-07-11 2003-07-24 Jakov Vaisman Treatment of premature ejaculation
AT512084A1 (de) 2011-10-20 2013-05-15 Univ Wien Tech Diazabicyclo- und diazaspiro-alkanderivate als phosphodiesterase-5 inhibitoren
EP3646871A1 (en) * 2018-10-30 2020-05-06 SEROJAC PME Handels GmbH Treatment and prevention of premature ejaculation (pe)
CN111297869A (zh) * 2020-04-23 2020-06-19 白文智 一种用于治疗早泄和勃起功能障碍的复方制剂

Also Published As

Publication number Publication date
DE60111254D1 (de) 2005-07-07
AU1514902A (en) 2002-05-27
EP1335730B1 (en) 2005-06-01
GB0028245D0 (en) 2001-01-03
ATE296631T1 (de) 2005-06-15
IL155521A0 (en) 2003-11-23
NZ525167A (en) 2005-02-25
BR0115413A (pt) 2003-10-07
JP2004520279A (ja) 2004-07-08
WO2002040027A1 (en) 2002-05-23
KR100595807B1 (ko) 2006-07-03
MXPA03003586A (es) 2003-07-14
PT1335730E (pt) 2005-09-30
PL362058A1 (en) 2004-10-18
CN1474692A (zh) 2004-02-11
CA2429114C (en) 2007-09-11
DE60111254T2 (de) 2006-05-04
HUP0301915A3 (en) 2007-03-28
TWI280132B (en) 2007-05-01
HUP0301915A2 (hu) 2003-09-29
CA2429114A1 (en) 2002-05-23
KR20030048476A (ko) 2003-06-19
EP1335730A1 (en) 2003-08-20
AU2002215149B2 (en) 2006-04-06
ZA200302947B (en) 2004-04-28
MY131573A (en) 2007-08-30

Similar Documents

Publication Publication Date Title
US20080153841A1 (en) Treatment of premature ejaculation
US20050065158A1 (en) Treatment of sexual dysfunction
US6476037B1 (en) L-arginine and phosphodiesterase (PDE) inhibitor synergism
US20030166662A1 (en) Treatment of the insulin resistance syndrome
EP1125582A2 (en) Use of estrogen agonists / antagonists for the treatment of sexual dysfunction
MXPA06000623A (es) Tratamiento de la disfuncion sexual.
JP2001302547A (ja) 女性の性機能不全を処置するための組成物および方法
AU8152301A (en) Use of PDE V inhibitors for improved fecundity in mammals
CA2419033A1 (en) Treatment of the insulin resistance syndrome with selective cgmp pde5 inhibitors
JP2007332156A (ja) 性的不能の治療に有効な組合せ
EP1020190A2 (en) Treatment of BPH with cGMP elevators
US6436944B1 (en) Combination effective for the treatment of impotence
BRPI0620234A2 (pt) combinação farmacêutica para o tratamento de luts que compreende um inibidor da pde5 e um antagonista muscarìnico
ES2240537T3 (es) Uso de inhibidores de pde5 para el tratamiento de la eyaculacion precoz.
US20030055070A1 (en) Phosphodiesterase type 5 (PDE5) inhibitors for the treatment of selective serotonin reuptake inhibitor (SSR) induced sexual dysfunction
EA007952B1 (ru) Применение ирбесартана для изготовления лекарств, которые пригодны для предупреждения или лечения лёгочной артериальной гипертензии
TW200404546A (en) Novel combination
AU2002215149A1 (en) Treatment of premature ejaculation
JP4533590B2 (ja) 脊髄損傷患者における疼痛又は痙性軽減用医薬組成物
HK1059043A (en) Treatment of premature ejaculation
AU2004233509A1 (en) Use of PDE V inhibitors for improved fecundity in mammals